Latest news with #NMA
See - Sada Elbalad
11 hours ago
- Entertainment
- See - Sada Elbalad
Pakistani Amb. in Cairo Meets Chairman of National Media Authority
Basant Ahmed Pakistani Ambassador to Cairo Aamir Shouket met with Chairman of National Media Authority (NMA/Maspero) in Egypt Mr. Ahmed Al-Moslemany, the Pakistani Embassy said on "X". The Ambassador lauded the Historical Brotherly relations between Pakistan and Egypt reflected in touching cultural landmarks, and thriving as a glowing evidence of strong Cultural Affinity, Literary and Artistic outlook of people of Pakistan and Egypt. Chairman of NMA Mr. Ahmed Al-Moslemany highlighted the Respect and Affection amongst Egyptian people for the Poet of The East Allama Muhammad Iqbal. The Chairman of NMA expressed strong admiration for Iqbal's Philosophy that influences Hearts and Sentimens, leaving an unforgettable imprint amongst Egyptian and Pakistan people through iconic performance of Kawkab AlSharq Umm Kulthum. During The meeting, it was agreed to reinvigorate existing mechanism of media cooperation under Cultural Cooperation Agreement between Pakistan and Egypt. It was also agreed to consolidate the existing cultural and media cooperation while simultaneously exploring avenues for joint production aimed at bringing the brotherly people of the two countries more closer. read more Gold prices rise, 21 Karat at EGP 3685 NATO's Role in Israeli-Palestinian Conflict US Expresses 'Strong Opposition' to New Turkish Military Operation in Syria Shoukry Meets Director-General of FAO Lavrov: confrontation bet. nuclear powers must be avoided News Iran Summons French Ambassador over Foreign Minister Remarks News Aboul Gheit Condemns Israeli Escalation in West Bank News Greek PM: Athens Plays Key Role in Improving Energy Security in Region News One Person Injured in Explosion at Ukrainian Embassy in Madrid News China Launches Largest Ever Aircraft Carrier Sports Former Al Zamalek Player Ibrahim Shika Passes away after Long Battle with Cancer Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt Business Fear & Greed Index Plummets to Lowest Level Ever Recorded amid Global Trade War Arts & Culture Zahi Hawass: Claims of Columns Beneath the Pyramid of Khafre Are Lies News Flights suspended at Port Sudan Airport after Drone Attacks Videos & Features Video: Trending Lifestyle TikToker Valeria Márquez Shot Dead during Live Stream News Shell Unveils Cost-Cutting, LNG Growth Plan Technology 50-Year Soviet Spacecraft 'Kosmos 482' Crashes into Indian Ocean News 3 Killed in Shooting Attack in Thailand
Al-Ahram Weekly
11 hours ago
- Entertainment
- Al-Ahram Weekly
Egypt's media chief discusses translating Egyptian TV dramas into Urdu - Screens - Arts & Culture
Head of Egypt's National Media Authority (NMA), Ahmed Al-Meslemany, has proposed translating Egyptian television dramas into Urdu, Pakistan's official language. Al-Meslemany discussed the initiative with Pakistan's ambassador to Egypt, Aamir Shouket, during the latter's visit to the Egyptian state Television broadcaster (Maspero) this week. Ambassador Shaukat toured the Naguib Mahfouz Studio at Maspero, where the two sides discussed expanding bilateral media and broadcasting cooperation. Al-Meslemany outlined the NMA's vision for translating selected Egyptian dramas into Urdu, which he noted is one of the world's most widely spoken languages. Ambassador Shaukat welcomed the initiative and suggested that the Urdu-subtitled Egyptian series could be broadcast on Pakistan's national television channels. Follow us on: Facebook Instagram Whatsapp Short link:
Associated Press
3 days ago
- Health
- Associated Press
NMDP's ACCESS Trial Results Published in Journal of Clinical Oncology, Demonstrating Strong Outcomes with Mismatched Unrelated Donors in Adult Stem Cell Transplantation
MINNEAPOLIS--(BUSINESS WIRE)--Jun 17, 2025-- Results from the ACCESS (Allogeneic Cell Transplantation Clinical Evaluation of Stem Cell Sources) study, a multicenter Phase II clinical trial sponsored by NMDP SM, a global nonprofit leader in cell therapy, and conducted by its collaborative research program, CIBMTR® (Center for International Blood and Marrow Transplant Research®), were published in the peer-reviewed Journal of Clinical Oncology. The results demonstrate that post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis enables safe and effective hematopoietic cell transplantation (HCT) from mismatched unrelated donors (MMUD), significantly expanding access to curative therapy for patients with blood cancers. Evaluating outcomes in two conditioning intensity groups—myeloablative (MAC) and reduced-intensity/nonmyeloablative (RIC/NMA)—the study found there was no significant difference in overall survival (OS) between patients with 7/8 HLA-matched donors and those with <7/8 matches, supporting broader donor eligibility. The one-year OS was 83.8% for MAC and 78.6% for RIC/NMA recipients. These outcomes were comparable to, or better than, historical 8/8 matched donor benchmarks (75%). 'These study results are a major step forward in making allogeneic peripheral blood stem cell transplantation more accessible for all patients who need a lifesaving procedure,' said Monzr M. Al Malki, M.D., Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope and ACCESS study co-chair. 'By demonstrating that mismatched unrelated donors can be used safely and effectively, we are opening the door to curative therapy for patients who historically had limited or no donor options. The findings published also lay the groundwork for future Phase III trials comparing MMUD transplantation to other alternative donor strategies.' The trial enrolled 145 adult patients with high-risk hematologic malignancies across 21 U.S. transplant centers, with 59% self-identifying as members of underrepresented racial or ethnic groups. Participants received peripheral blood stem cell (PBSC) grafts from MMUDs and were treated with a standardized PTCy-based GVHD prophylaxis regimen. Low rates of severe GVHD were also observed, with grade III-IV acute GVHD at six months occurring in only 8% (MAC) and 10% (RIC/NMA) and severe chronic GVHD at 12 months in only 3% (MAC) and 4% (RIC/NMA) of patients. The pool of study participants included a high representation of socially vulnerable populations, with many patients reporting financial hardship and reduced physical function at baseline. NMDP-led Donor for All research Historically, finding an available matched, unrelated donor on international registries has been limited for patients with ethnically diverse ancestry— from as low as 29% for Black or African American patients and 48% for Latino and Hispanic patients versus 79% for non-Hispanic White patients. NMDP's network of transplant centers, many of which participate in CIBMTR trials, are bringing new research to light that is challenging previously established HCT science. To improve outcomes, NMDP is sponsoring a series of clinical trials studying the use of PTCy GVHD prophylaxis in MMUD HCT (patients matched at 4/8 to 7/8 alleles). 'Our Donor for All research is transforming cell therapy as well as redefining donor eligibility and transplant accessibility – helping close the donor gap and extend curative therapies to every patient who needs a life-saving transplant,' Steven Devine, MD, chief medical officer, NMDP, and senior scientific director, CIBMTR, and a senior author of the study, added. About CIBMTR® CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a nonprofit research collaboration between NMDP SM, in Minneapolis, and the Medical College of Wisconsin®, in Milwaukee. CIBMTR collaborates with the global scientific community to increase survival and enrich quality of life for patients. CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of centers, and a unique database of long-term clinical data for more than 675,000 people who have received hematopoietic cell transplantation and other cellular therapies. Learn more at About NMDP SM At NMDP SM, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world's most diverse registry and our extensive network of transplant partners, physicians and caregivers, we're expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives. Learn more at View source version on CONTACT: Media contact: Jess Ayers [email protected] KEYWORD: UNITED STATES NORTH AMERICA MINNESOTA INDUSTRY KEYWORD: ONCOLOGY HEALTH STEM CELLS GENERAL HEALTH CLINICAL TRIALS RESEARCH SCIENCE SOURCE: NMDP Copyright Business Wire 2025. PUB: 06/17/2025 10:14 AM/DISC: 06/17/2025 10:14 AM
Business Upturn
6 days ago
- Business
- Business Upturn
Nimanode Surpasses Crypto Presales, Eyes 10X Growth Post-Launch as Major Investors Flock to the XRP DeFi Landscape
LEEDS, United Kingdom, June 14, 2025 (GLOBE NEWSWIRE) — Nimanode , the first no-code AI agent platform built natively on the XRP Ledger (XRPL), is gaining momentum with its ongoing $NMA token presale. As investor confidence in AI infrastructure and XRP-based innovation grows, highly anticipated Nimanode (NMA) Presale has so far surpassed expectations, rapidly filling 20% of its softcap which has fuelled intense investor FOMO. Nimanode is drawing serious attention from early adopters seeking exposure to the next phase of Web3 automation. With anticipation of a major breakout post-launch, early participants are moving quickly to secure $NMA tokens at presale pricing. Join $NMA Presale Why the XRP Community Is Flocking to Nimanode Nimanode is capturing attention for good reason: it's pioneering zero-code, on-chain AI agents that can automate complex blockchain tasks from deploying smart contracts and managing DeFi strategies to running real-time compliance checks and providing intelligent customer support. The platform's unique value lies in its accessibility. Anyone regardless of coding ability can create and monetize autonomous AI agents, all powered by the speed and cost-efficiency of the XRPL. Unlike static automation or off-chain bots, Nimanode agents operate on-chain, interact with smart contracts, and generate on-chain earnings; creating a new form of programmable, decentralized labor. Presale Demand Up as Investors Target $NMA for 10X Growth Nimanode's $NMA being the core utility engine of the Nimanode Ecosystem through its usage on the Nimanode Agent Marketplace and Agent Builder was not only what has drawn investors towards it. However with a capped supply of only 200 million $NMA tokens, built-in scarcity and strong long-term value potential are designed into its foundation. the core utility engine As the market is currently clouded by volatility and corrections, Nimanode's presale is emerging as a rare bright spot. Sparking strong FOMO across the XRP community and beyond as investors position themselves early in what many believe could be the next 100X breakout on XRPL. To put it in perspective, XRP once saw an explosive 137,000% surge during the 2017–2018 bull market. Now, as the XRP ecosystem rebounds—with the token retracing back to $2.20—Nimanode's emergence offers a timely opportunity to capture investor interest around intelligent automation, agent-powered DeFi, and tokenized real-world utilities built directly on XRPL. Market Analysts already predict strong upside upon exchange listing of $NMA as demand for agent-based infrastructure gains traction. This is a chance to invest in $NMA before its Listing at 25% higher than Presale value, however whales position for more as they eye a 10X surge on Launch. Join $NMA Presale Don't Miss Out Nimanode Presale With a total of 90 million $NMA representing 45% of $NMA allocated for the presale, this marks a unique and promising chance to claim early access into one of XRP Ledger's most innovative projects, spearheading the AI ecosystem on the blockchain. Joining in the NimaNode Presale is quite straightforward Purchase XRP: Acquire XRP from reputable exchanges like Binance, Coinbase, or Bybit Send to an XRP-Compatible Wallet: Ensure you have a non-custodial wallet capable of receiving XRP native tokens Xaman recommended. Participate in the Presale: Visit the NimaNode presale page ( ), send your XRP to the provided presale address, and secure your $NMA tokens. As Nimanode Presale gains momentum, now is a perfect opportunity to position at the next wave of Blockchain innovation poised for massive gains through the integration of Web3 and AI. Connect with Nimanode Website: Twitter/X: Telegram: Documentation: Contact:Nick Lambert [email protected]
The Print
6 days ago
- Politics
- The Print
Sikkim Bhutia Lepcha Apex Committee appeals to Nepal to respect sanctity of Mt Kanchenjunga
According to SIBLAC, Mt Kanchenjunga is not merely a geographical landmark but a sacred entity, revered as a guardian deity by the Sikkimese people. In two separate letters addressed to Nepal's tourism minister and the NMA president, SIBLAC urged the authorities to reconsider their decision to allow a joint mountaineering expedition involving climbers from India and Nepal, which is scheduled to begin from Nepal on June 18 under the aegis of India's National Institute of Mountaineering and Adventure Sports (NIMAS). Gangtok, Jun 14 (PTI) The Sikkim Bhutia Lepcha Apex Committee (SIBLAC) on Saturday appealed to the Nepal government and the Nepal Mountaineering Association (NMA) to immediately halt a planned expedition to Mt Kanchenjunga, citing the mountain's deep spiritual and cultural significance to the indigenous communities of Sikkim. The organisation noted that the mountain is central to the state's religious and cultural heritage, and is associated with annual prayers and ceremonies deeply rooted in local traditions. The letters further reference the 2001 notification by the Government of Sikkim, which banned mountaineering activities on the mountain out of respect for local beliefs. They also invoked provisions of Article 371F and Sikkim's special status within the Indian Constitution, emphasising the protection of indigenous customs and religious sentiments. SIBLAC warned that any expedition involving summiting Kanchenjunga, particularly from Nepal, could be perceived as a serious cultural violation, and called for the mountain to be treated with spiritual reverence rather than as a site for adventure tourism. The committee requested both governments to act with sensitivity and uphold the sacred status of the mountain. The appeal concluded with a request to halt the planned ascent and preserve the spiritual and environmental sanctity of the region, while respecting the sentiments of the Sikkimese people. SIBLAC had earlier urged the Sikkim government to enforce the standing prohibition on climbing Mt Kanchenjunga, citing the sacred status of the mountain and the legal protections already in place. It had condemned the summit attempt by a group of mountaineers in May. PTI COR ACD This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
